VSTM May 2024 13.000 call
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.4500 |
| Strike | 13.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.2000 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 32 |
Business WireVerastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
BOSTON, May 07, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024 at 3:35 pm EDT.
Business WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
BOSTON, April 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company.
Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 04, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have
